Get the Stockscreener App
0.423
3.49%
-0.0153
Evogene Ltd stock is traded at $0.423, with a volume of 32,935.
It is down -3.49% in the last 24 hours and down -31.66% over the past month.
Evogene Ltd is a computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. The company established its technology, the Computational Predictive Biology (CPB) platform. The CPB platform is designed to computationally discover and develop life-science products based on microbes, small molecules, and genetic elements as the core components for such products. It holds several subsidiaries utilizing the CPB platform for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits, and ag-solutions for castor oil production. It generates maximum revenue from the industrial segment, followed by Agriculture.
See More
Previous Close:
$0.4383
Open:
$0.4298
24h Volume:
32,935
Relative Volume:
0.03
Market Cap:
$5.12M
Revenue:
$1.84M
Net Income/Loss:
$-17.51M
P/E Ratio:
-0.3054
EPS:
-1.3849
Net Cash Flow:
$-17.30M
1W Performance:
-3.62%
1M Performance:
-31.66%
6M Performance:
-62.89%
1Y Performance:
-67.95%
1-Day Range:
$0.414
$0.4303
1-Week Range:
$0.4117
$0.4499
52-Week Range:
$0.37
$1.50
Evogene Ltd Stock (EVGN) Company Profile
Compare EVGN vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EVGN
Evogene Ltd
|
0.423 | 5.20M | 1.84M | -17.51M | -17.30M | -1.3849 |
VRTX
Vertex Pharmaceuticals Inc
|
520.41 | 134.02B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
670.00 | 68.59B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
925.27 | 58.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.90 | 41.76B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.76 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
Evogene Ltd Stock (EVGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-08-21 | Initiated | ROTH Capital | Buy |
| Jul-29-21 | Initiated | Aegis Capital | Buy |
| Dec-01-20 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-16-13 | Initiated | Oppenheimer | Outperform |
Evogene Ltd Stock (EVGN) Latest News
Why Did EVGN Shares Drop More Than 14% Today? - Stocktwits
Evogene | 6-K: Report of foreign private issuer (related to financial reporting) - Moomoo
Price to book forward of Evogene Ltd. – NASDAQ:EVGN - TradingView
Enterprise value to revenue forward of Evogene Ltd. – NASDAQ:EVGN - TradingView
Evogene Ltd Actuals & Estimates (NASDAQ:EVGN) - TradingView
EVGN Forecast — Price Target — Prediction for 2027 - TradingView
Evogene completes milestone in Google Cloud collaboration By Investing.com - Investing.com South Africa
Evogene completes milestone in Google Cloud collaboration - Investing.com
Evogene Announces Major Milestone in Its Coll - Moomoo
Evogene Ltd. And Google Cloud Announces Major Milestone In Collaboration Advancing ChemPass AI Toward Autonomous Small Molecule Discovery And Optimization - marketscreener.com
SEC Filings | Track, Search, and Analyze Public Company Disclosures - SECFilings.com
Evogene Ltd (EVGN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Evogene StockWeekly review and sector context after recent Q1 update - AD HOC NEWS
Evogene Ltd (EVGN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Evogene Ltd (EVGN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Evogene Ltd (EVGN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Evogene Ltd (EVGN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Evogene Ltd (EVGN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Evogene Ltd (EVGN) Institutional Confidence - TradingKey
Evogene Ltd (EVGN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Evogene Ltd (EVGN) Valuation: PE, PB & Fair Value Analysis - TradingKey
EVGN Q1 2026 Earnings: EPS Misses Estimates by a Wide Margin Amid Weak Operating PerformancePretax Income Report - newsline.com
Evogene Showcases AI-Driven ChemPass Platform and Expanded Google Cloud Collaboration in New Investor Deck - TipRanks
Evogene (EVGN) showcases ChemPass AI drug and ag-chem discovery strategy - Stock Titan
EVGN Q1 2026 Earnings: Deep EPS Miss Raises Investor Concerns Amid Pre-Revenue StageTrough Earnings Signal - newsline.com
Biomica CEO Set to Attend JP Morgan Healthcare Week in San Franc - GuruFocus
Evogene Shares Slip 2.6% as Biotech Stock Tests Key Support Level (EVGN)Flat Correction - newsline.com
Evogene Sets Up $2.9 Million At-the-Market Share Offering With A.G.P. - The Globe and Mail
Evogene enters sales agreement for at-the-market offering of up to $2.93 million - Investing.com Australia
Evogene enters sales agreement for at-the-market offering of up to $2.93 million By Investing.com - Investing.com India
Evogene Ltd. (NASDAQ: EVGN) launches $2.93M ATM program with A.G.P. - Stock Titan
Evogene (EVGN) launches $2.93M at-the-market share offering with A.G.P. - Stock Titan
EVGN Q1 2026 Earnings: Significant EPS Miss Amid Ongoing Operational ChallengesBasic EPS Analysis - newsline.com
Evogene Q1 revenue falls to $0.3 million amid strategic shift - scanx.trade
Full Transcript: Evogene Q1 2026 Earnings CallEvogene (NASDAQ:EVGN) - Benzinga
Inside Evogene’s AI drug hunt: ChemPass platform hits BIO 2026 stage - Stock Titan
Evogene to Present Its Pharma Division Achievements at the BIO International Convention - PR Newswire
Earnings Call Summary | Evogene(EVGN.US) Q1 2026 Earnings Conference - 富途牛牛
EVGN Stock Price, Quote & Chart | EVOGENE LTD (NASDAQ:EVGN) - ChartMill
EVGN Q1 2026 Earnings: EPS Misses Estimates Significantly, Stock DeclinesProfit Warning Alert - newsline.com
Evogene completes phase 1 trial of BMC128 cancer treatment By Investing.com - Investing.com South Africa
Evogene: Q1 Earnings Snapshot - AOL.com
Evogene (EVGN) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - MarketBeat
Evogene says Phase 1 clinical study of BMC128 met primary endpoint - TipRanks
Evogene completes phase 1 trial of BMC128 cancer treatment - Investing.com
Evogene Announces Successful Completion of Phase 1 Clinical Study of BMC128, a Rationally Designed Live Bacterial Product, in Combination with Nivolumab by its Subsidiary Biomica - PR Newswire
Experimental gut bacteria cancer therapy shows early anti-tumor signal - Stock Titan
Evogene Ltd stock (IL0010831684): Shares trade quietly as investors await next catalysts - AD HOC NEWS
Evogene (EVGN) Edges Lower, Testing Key Support at $0.66Dealer Delta - newsline.com
Evogene Ltd (EVGN) Holding Near Support After Modest DeclineFibonacci Arc - The Legal Advocate
EVGN Q1 2026 Earnings: Significant EPS Miss Highlights Operational ChallengesShare Repurchase Impact - The Legal Advocate
Evogene Ltd Stock (EVGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.82%
0.85%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):